Prostate Cancer


Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.

Trial overview


Prostate cancer


Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer.

Eligibility criteria

  • Metastatic Castration Resistant Prostate Cancer not previously treated in that setting
  • Rising PSA
  • High risk for early failure on enzalutatmide

Study details

Eligibility will be assessed based on screening GaPSMA PET and FDG PET. Once eligible you will be randomised to enzaluatamide alone or enzalutamide with LuPSMA. LuPSMA is a nuclear medicine targeted therapy. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.


Further information

For more information regarding this clinical trial click here.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.